The state of Rhode Island has settled opioid claims against generic pharmaceutical manufacturer Teva Pharmaceutical Industries Ltd. just before its lawyers were set to begin opening statements to jurors on Monday.
Rhode Island Attorney General Peter Neronha said the Teva agreement and another settlement with Allergan together totaled about $107 million in value. That includes $28.5 million in cash: Teva will provide $21 million, while $7.5 million will come from Allergan. Both settlements also provide 1 million nasal sprays of Naxloxone, used to treat opioid overdoses, over the next decade.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
